Mesenchymal Stem Cells for Immune Modulation in Living Related Kidney Transplant
Renal Transplant Rejection
Enrolment: 17 · Results not recorded
Biologic · Bone-marrow mesenchymal stem cells (passages 2-5); cell therapy.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Renal Transplant Rejection
Enrolment: 17 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Collagenase IV induced intracerebral haemorrhage, 0.075 U in 0.4 microlitres phosphate buffered saline stereotactically injected into the right basal ganglia at 0.1 microlitres per minute
BM-MSC transplantation reduced day 3 haematoma volume and improved modified neurological severity and corner test scores at days 7 and 14 (p<0.05), with increased vimentin and EAAT1, reduced ALDH1L1 and reduced phospho-MST1 and phospho-YAP. YAP knockdown abolished the BM-MSC driven astrocyte prolif…
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.